Peer-reviewed veterinary case report
Differences in symptoms and survival for dog lymphoma types
By Aresu, L et al.·Published in Veterinary and comparative oncology·2015·Department of Comparative Biomedicine and Food Science, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Canine indolent and aggressive lymphoma: clinical spectrum with histologic correlation.
- Species:
- dog
Plain-English summary
A group of 63 dogs diagnosed with lymphoma, a type of cancer affecting the lymphatic system, received the same chemotherapy treatment. The most common type was diffuse large B-cell lymphoma, which often presented at an advanced stage. Dogs with aggressive B-cell lymphoma had a better chance of going into remission, while those with indolent T-cell lymphoma had a similar prognosis to aggressive cases. The average survival time varied, with aggressive B-cell lymphoma dogs living around 256 days after treatment. Understanding the different types of lymphoma is essential for proper diagnosis and treatment.
People also search for: dog lymphoma treatment · symptoms of lymphoma in dogs · dog cancer survival rates
Abstract
Sixty-three dogs with newly diagnosed lymphoma underwent complete staging and received the same chemotherapy. Diffuse large B-cell lymphoma was the leading histotype (44.4%), followed by peripheral T-cell lymphoma (20.6%). Indolent lymphomas accounted for 30.2% of cases. Most dogs with aggressive B-cell lymphoma had stage IV disease. Dogs with indolent and aggressive T-cell lymphoma had more often stage V disease and were symptomatic. Liver and bone marrow were predominantly involved in B-cell and T-cell lymphoma, respectively. The clinical stage was significantly related to substage, sex and total lactic dehydrogenase (LDH) levels. Aggressive B-cell lymphomas were more likely to achieve remission. Median survival was 55 days for aggressive and indolent T-cell lymphoma, 200 and 256 days for indolent and aggressive B-cell lymphoma, respectively. The prognosis of advanced indolent lymphoma does not appear to be appreciably different from that of aggressive disease. Familiarity with the various histotypes is critical to make the correct diagnosis and drive therapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23782432/